Cellectricon, a neuroscience drug discovery services provider, launched its new Neurotoxicity Testing Services, expanding its discovery platform to support the early safety assessment of drug candidates. With growing interest and feedback from the neuroscience community, the new service aims to enable drug developers to detect potential neurotoxic effects sooner, helping to reduce risk, save time, and improve confidence in candidate selection. The new testing services draw on Cellectricon’s n...